Nissan Motor raises $4.5 billion in bond sales, term sheet shows
HONG KONG (Reuters) -Japan's Nissan Motor has raised $4.52 billion in U.S. dollar- and euro-denominated senior unsecured bonds, according to a term sheet reviewed by Reuters on Friday, with the proceeds intended to refinance existing debt.
The issuance comes about a week after Reuters reported that Nissan has asked some suppliers to allow it to delay payments to free up short-term funds, highlighting its scramble to boost cash.
According to the term sheet, $3 billion was raised through three U.S. dollar tranches with 5-, 7-, and 10-year maturities, while a further 1.3 billion euros ($1.52 billion) were issued in four- and eight-year tranches.
The U.S. dollar 5-year bonds were priced at 355 basis points (bps) over Treasuries, the 7-year at 360 bps, and the 10-year at 376 bps.
The coupons are 7.5% for the five-year tranche, 7.75% for the seven-year tranche and 8.125% for the 10-year tranche, the term sheet showed.
Citi, Bank of America and HSBC were joint book runners for the bond sales, according to the term sheet.
The automaker faces around 700 billion yen ($4.76 billion) in debt maturing this financial year and has been downgraded to "junk" status by all three major credit-rating agencies.
($1 = 0.8563 euros)
($1 = 146.9400 yen)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Astera Labs Announces Third Quarter 2025 Financial Conference Participation
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced its participation in financial conferences for the third quarter 2025. Deutsche Bank 2025 Technology Conference on Aug. 28, 2025. Astera Labs' presentation is scheduled for 12:30 pm PT. Citi's 2025 Global TMT Conference on Sept. 4, 2025. Astera Labs' presentation is scheduled for 8:50 am ET. A webcast of each session will be made available on Astera Labs' investor relations website at About Astera Labs Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions grounded in open standards. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs' Intelligent Connectivity Platform integrates CXL®, Ethernet, PCIe®, and UALink™ semiconductor-based technologies with the company's COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. Discover more at IR CONTACT: Leslie
Business Wire
25 minutes ago
- Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3 rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:30 a.m. ET Live webcasts of the fireside chats will be available by visiting the 'Investors & Media' section of the Arcus Biosciences website at Replays will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit
Axios
an hour ago
- Axios
Nashville Pride faces catastrophic shortfall after corporations pull funding
Nashville Pride's future is in jeopardy after corporate sponsorships cratered this year, creating a catastrophic budget shortfall for the LGBTQ+ nonprofit. Why it matters: The organization launched an emergency fundraiser to "save Nashville Pride." Organizers say if they don't hit their $250,000 goal, "we risk losing not just a weekend of celebration, but a safe space for tens of thousands of LGBTQ+ people and allies all year long." Nashville Pride set a deadline of Oct. 11, which is National Coming Out Day. The big picture: Pride festivals nationwide have been pushed to the brink this year. Longtime corporate allies are backing away and pulling funding. The trend is fueled by the Trump administration's opposition to diversity, equity, and inclusion. State of play: In Nashville, funding from corporate sponsors dropped by $270,000 in 2025. That's down 40% from 2024. Nashville Pride organizers said many of the losses were unexpected, last-minute decisions. Vanderbilt University Medical Center, which previously contributed medical support at the festival, pulled out in mid-May, only a few weeks before this year's festival, Pride spokesperson Brady Ruffin tells Axios. As a result, organizers had to find and pay for a new provider, Ruffin says, racking up $30,000 in expenses. A VUMC spokesperson declined to comment. Between the lines: Past Nashville Pride sponsor Nissan, one of the companies that stepped back this year, said its Pride retreat was part of a broad review of marketing and sales spending, per a Nissan spokesperson. Zoom in: Bad weather during this year's festival exacerbated revenue problems. Organizers said storms cut attendance by more than 15,000 people. What they're saying:"These challenges left Nashville Pride with a gap that no single organization can fix," Nashville Pride board president Tina Tousignant, said in a statement Wednesday. Driving the news: Nashville Pride said growing opposition to LGBTQ+ issues at the state and federal levels underscored the significance of the fundraising effort. Tennessee has long been seen as a leader in anti-transgender policies. Lawmakers have pushed restrictions on drag queens and gender-affirming health care. The Nashville-based Southern Baptist Convention passed a resolution this year supporting efforts to reverse Obergefell v. Hodges, the landmark case that legalized same-sex marriage 10 years ago. "Pride isn't just a party — it's survival," Nashville Pride vice president Alycia Ehimen said in the Wednesday statement.
